Search This Blog

Saturday, September 29, 2018

Nearly 4 in 10 people on Medicare skip their doctor’s visits


Medicare can help defray retirees’ health-care costs, but it’s no panacea. Some beneficiaries in the program are delaying medical attention due to the expense.
Nearly 4 out of 10 Medicare enrollees have admitted to skipping or delaying medical care, or failing to fill a prescription, in order to save money, according to a recent survey from eHealth.com.
In August, the private online health insurance exchange did an email poll of 1,020 individuals who were 65 and over, and had purchased a Medicare insurance product through the company.
“When it comes to understanding Medicare plan options and choosing one, it’s pretty complex and overwhelming,” said Andrew Shea, vice president of Medicare products at eHealth.com.
“Deductibles can sometimes be surprising to people with Medicare plans, and they don’t fully understand how the deductible works and the concept of having to float a decent amount of money before the coverage really kicks in,” he said.
Here are some of the expenses that are driving beneficiaries’ decision to avoid the doctor.

Paying for prescriptions

Of the participants who said they skipped the pharmacy due to the cost of drugs, 45 percent said that both the brand name and the generic medication were too costly.
Indeed, one of the costliest generics is atorvastatin — a widely used drug that treats high cholesterol, according to GoodRx.com, a site that provides discounts on prescription drugs.
The cash price for a monthly supply of the medication costs around $121, GoodRx.com found. Medicare Part D, which covers prescription drugs, can help lower this cost significantly.

Deductibles and more

Costs related to Medicare premiums only tell part of the story.
You probably know that, this year, individual filers with up to $85,000 ($170,000 for married and filing jointly) in modified adjusted gross income in 2016 can expect to pay $134 per month for Medicare Part B.
Those with higher incomes will pay more. See below.

Medicare Part B premiums

INDIVIDUAL TAX FILERS*
MARRIED, FILE TAXES JOINTLY*
MARRIED, FILE TAXES SEPARATELY*
WHAT YOU PAY MONTHLY IN 2018
$85,000 or less$170,000 or less$85,000 or less$134
Above $85,000 up to $107,000Above $170,000 up to $214,000Not applicable$187.50
Above $107,000 up to $133,500Above $214,000 up to $267,000Not applicable$267.90
Above $133,500 up to $160,000Above $267,000 up to $320,000Not applicable$348.30
Above $160,000Above $320,000Above $85,000$428.60
Deductibles and copays are keeping beneficiaries up at night. About half of the participants in eHealth.com’s study said they were worried about these costs.
Individuals enrolled in Medicare Part A, which covers hospital stays and skilled nursing, face a deductible of $1,340 per benefit period when they’re admitted to the hospital.
Beneficiaries of Medicare Part B, which covers doctor’s visits and other outpatient services, are subject to an $183 annual deductible in 2018. Once you’ve paid that amount, you’re responsible for 20 percent of the Medicare-approved amount for services.

Eyes and ears

One popular misconception among Medicare beneficiaries is that they’ll be covered for everything once they’ve enrolled in the health-care program.
That’s not so. Your dentures, routine vision exams and eyeglasses, as well as hearing aids, generally aren’t covered under original Medicare.
In all, 44 percent of the participants in eHealth’s study said that they were worried about the cost of dental and vision services.
Some Medicare Advantage plans may offer hearing and eye benefits. Beneficiaries should examine the depth of that coverage if they get it, said Shea.
Enrollees can also purchase standalone dental, vision and hearing insurance coverage, which averages between $35 and $45 a month at eHealth, he said.

What you should know

Don’t phone in your Medicare enrollment this fall. Here are a few recommendations to follow, according to Shea.
• Don’t assume last year’s plan is still right for you. Premiums go up, and the terms of your coverage can change. Review your plan during open enrollment.
• Check your mail. Around September, enrollees in Medicare Advantage plans receive an annual notice of change document that will provide a walkthrough of coverage updates. Take the time to read it, and call your insurer to clarify anything hard to understand.
• Talk to your doctor. If you’re skipping medical treatment due to cost, explain your situation to your physician. He or she may be able to point you toward less expensive treatment options, as well as community resources to help you deal with the expense.
Avoiding medical attention now can lead to mounting problems — and bills — down the road.
“One of the worst things is to be penny-wise and pound-foolish, ending up in the hospital with a $5,000 out-of-pocket bill,” said Shea.

Tim Berners-Lee’s new plan to upend the World Wide Web


Last week, Tim Berners-Lee, inventor of the World Wide Web, asked me to come and see a project he has been working on almost as long as the web itself. It’s a crisp autumn day in Boston, where Berners-Lee works out of an office above a boxing gym. After politely offering me a cup of coffee, he leads us into a sparse conference room. At one end of a long table is a battered laptop covered with stickers. Here, on this computer, he is working on a plan to radically alter how all of us live and work on the web.
“The intent is world domination,” Berners-Lee says with a wry smile. The British-born scientist is known for his dry sense of humor. But in this case, he is not joking.
This week, Berners-Lee will launch Inrupt, a startup that he has been building, in stealth mode, for the past nine months. Backed by Glasswing Ventures, its mission is to turbocharge a broader movement afoot, among developers around the world, to decentralize the web and take back power from the forces that have profited from centralizing it. In other words, it’s game on for Facebook, Google, Amazon. For years now, Berners-Lee and other internet activists have been dreaming of a digital utopia where individuals control their own data and the internet remains free and open. But for Berners-Lee, the time for dreaming is over.
“We have to do it now,” he says, displaying an intensity and urgency that is uncharacteristic for this soft-spoken academic. “It’s a historical moment.” Ever since revelations emerged that Facebook had allowed people’s data to be misused by political operatives, Berners-Lee has felt an imperative to get this digital idyll into the real world. In a post published this weekend, Berners-Lee explains that he is taking a sabbatical from MIT to work full time on Inrupt. The company will be the first major commercial venture built off of Solid, a decentralized web platform he and others at MIT have spent years building.

A NETSCAPE FOR TODAY’S INTERNET

If all goes as planned, Inrupt will be to Solid what Netscape once was for many first-time users of the web: an easy way in. And like with Netscape, Berners-Lee hopes Inrupt will be just the first of many companies to emerge from Solid.
“I have been imagining this for a very long time,” says Berners-Lee. He opens up his laptop and starts tapping at his keyboard. Watching the inventor of the web work at his computer feels like what it might have been like to watch Beethoven compose a symphony: It’s riveting but hard to fully grasp. “We are in the Solid world now,” he says, his eyes lit up with excitement. He pushes the laptop toward me so I too can see.
On his screen, there is a simple-looking web page with tabs across the top: Tim’s to-do list, his calendar, chats, address book. He built this app–one of the first on Solid–for his personal use. It is simple, spare. In fact, it’s so plain that, at first glance, it’s hard to see its significance. But to Berners-Lee, this is where the revolution begins. The app, using Solid’s decentralized technology, allows Berners-Lee to access all of his data seamlessly–his calendar, his music library, videos, chat, research. It’s like a mashup of Google Drive, Microsoft Outlook, Slack, Spotify, and WhatsApp.
The difference here is that, on Solid, all the information is under his control. Every bit of data he creates or adds on Solid exists within a Solid pod–which is an acronym for personal online data store. These pods are what give Solid users control over their applications and information on the web. Anyone using the platform will get a Solid identity and Solid pod. This is how people, Berners-Lee says, will take back the power of the web from corporations.
[Image courtesy of Tim Berners-Lee]
For example, one idea Berners-Lee is currently working on is a way to create a decentralized version of Alexa, Amazon’s increasingly ubiquitous digital assistant. He calls it Charlie. Unlike with Alexa, on Charlie people would own all their data. That means they could trust Charlie with, for example, health records, children’s school events, or financial records. That is the kind of machine Berners-Lee hopes will spring up all over Solid to flip the power dynamics of the web from corporation to individuals.

A NEW REVOLUTION FOR DEVELOPERS?

Berners-Lee believes Solid will resonate with the global community of developers, hackers, and internet activists who bristle over corporate and government control of the web. “Developers have always had a certain amount of revolutionary spirit,” he observes. Circumventing government spies or corporate overlords may be the initial lure of Solid, but the bigger draw will be something even more appealing to hackers: freedom. In the centralized web, data is kept in silos–controlled by the companies that build them, like Facebook and Google. In the decentralized web, there are no silos.
Starting this week, developers around the world will be able to start building their own decentralized apps with tools through the Inrupt site. Berners-Lee will spend this fall crisscrossing the globe, giving tutorials and presentations to developers about Solid and Inrupt. (There will be a Solid tutorial at our Fast Company Innovation Festival on October 23.)
“What’s great about having a startup versus a research group is things get done,” he says. These days, instead of heading into his lab at MIT, Berners-Lee comes to the Inrupt offices, which are currently based out of Janeiro Digital, a company he has contracted to help work on Inrupt. For now, the company consists of Berners-Lee; his partner John Bruce, who built Resilient, a security platform bought by IBM; a handful of on-staff developers contracted to work on the project; and a community of volunteer coders.
Later this fall, Berners-Lee plans to start looking for more venture funding and grow his team. The aim, for now, is not to make billions of dollars. The man who gave the web away for free has never been motivated by money. Still, his plans could impact billion-dollar business models that profit off of control over data. It’s not likely that the big powers of the web will give up control without a fight.
When asked about this, Berners-Lee says flatly: “We are not talking to Facebook and Google about whether or not to introduce a complete change where all their business models are completely upended overnight. We are not asking their permission.”
https://www.fastcompany.com/90243936/exclusive-tim-berners-lee-tells-us-his-radical-new-plan-to-upend-the-world-wide-web

Top Five Trending Kidney Care Topics from DaVita Medical Insights


DaVita Kidney Care, a division of DaVita Inc. (NYSE: DVA), a leading provider in kidney care services, today shared its “top five” list from the DaVita Medical Insights podcast and blog. Both are forums to discuss trending news and issues in kidney care and were created by physicians, for physicians.
The top five stories include:
  • The Self-Regulating Bioartificial Kidney – Bryan Becker, M.D., discusses The Kidney Project, an initiative officially launched in 2015 by nephrologists William Fissell, M.D. and David Humes, M.D. “to create a small, surgically-implanted and free-standing bioartificial kidney,” which would help settle organ supply barriers.
  • Effectively Managing Kidney Patients’ Transitions of Care – Ananda Harrison interviews Dr. Becker on the importance of managing care when a patient moves within or between health care settings, across states of health and between clinicians, and the physician’s role in this process.
  • Why Physicians Choose Nephrology – Physician leaders for DaVita recount why they chose to become nephrologists in honor of National Doctors Day.
  • Electronic Health Records: Past, Current and Future Landscape – Electronic health records (EHRs) first started to appear in the 1970s, yet physicians have been slow to adopt the technology because of cost and workflow disruption. Listen to Adam Weinstein, M.D., cover the evolution of EHRs, what the future potentially holds for this technology and where its full functionality may ultimately settle.
  • Study: The Impact of Missed Dialysis Treatments on Clinical Outcomes – A study conducted by DaVita Clinical Research aimed to identify the prevalence of in-center hemodialysis absenteeism and its effects on clinical outcomes. Steve M. Brunelli, M.D., MSCE reviews the key takeaways, including how missed treatments impact hospitalization and mortality among dialysis patients.

Cidara initiates Phase 3 trial to evaluate efficacy, safety of antifungal


Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, today announced that the first trial site has been activated for ReSTORE, a Phase 3 clinical trial evaluating the efficacy and safety of the company`s lead antifungal, rezafungin, to treat candidemia and invasive candidiasis. Rezafungin is a novel echinocandin antifungal being developed as a once-weekly, high-exposure therapy for the treatment and prevention of serious invasive fungal infections.
“Given the compelling data from our Phase 2 program, we are very pleased to initiate our global Phase 3 program of rezafungin,” said Jeffrey Stein, Ph.D., president and chief executive officer of Cidara. “Difficult-to-treat, invasive Candida infections are associated with a high mortality and affect the most vulnerable patients. Rezafungin has the potential to be the first new antifungal approved for this indication in over a decade and, given how the drug works, it has the potential to improve outcomes for patients and allow them to leave the hospital earlier, resulting in reduced healthcare costs.”
ReSTORE is a global, randomized, double-blind, controlled Phase 3 pivotal clinical trial evaluating the efficacy and safety of once-weekly intravenous dosing of rezafungin compared to once-daily dosing of caspofungin in patients with candidemia and/or invasive candidiasis. The trial design will be similar to the company`s Phase 2 STRIVE study, which met its primary safety and efficacy objectives. The ReSTORE trial is designed to evaluate one rezafungin dosing regimen of 400 milligrams (mg) for the first week followed by 200 mg of rezafungin once weekly for up to four weeks in total. This treatment arm will be compared to caspofungin in a 1:1 randomization.
The primary efficacy endpoint of ReSTORE, which will be used for a U.S. Food and Drug Administration (FDA) New Drug Application submission, is all-cause mortality at day 30. The primary efficacy endpoint for the European Medicines Agency (EMA) is expected to be global response at day 14.
“I am very enthusiastic about the initiation of this important trial of rezafungin as a once-weekly echinocandin which may offer a new solution for patients and physicians to treat serious invasive Candida infections,” said Cornelius J. Clancy, M.D., Associate Professor of Medicine and Director of the Mycology Research Unit and XDR Pathogen Lab at the University of Pittsburgh. “There is an urgent and growing need for new therapeutic approaches for these infections, which typically afflict highly vulnerable patients, including those who are critically ill and have compromised immune systems. Rezafungin has the potential to overcome the significant limitations associated with current standards of care such as sub-optimal dosing, increasing resistance, drug-drug interactions and toxicities, all of which complicate therapy in patients who are already ill.”
The ReSTORE trial will enroll approximately 184 modified intent-to-treat, or mITT, patients and is expected to generate topline data in 2020. This global trial is anticipated to be conducted at approximately 100 clinical trial centers across the United States, Europe, Asia and Australia.

Intra Cellular Therapies in New Drug Application for Schizophrenia Med


Intra-Cellular Therapies, Inc. (Nasdaq:ITCI), a biopharmaceutical company focused on the development of therapeutics for central nervous system (CNS) disorders, today announced that the Company has completed the rolling submission of its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lumateperone, a once-daily, oral investigational medicine with a novel mechanism of action for the treatment of schizophrenia. The NDA submission is supported by data from 20 clinical trials and more than 1,900 subjects exposed to lumateperone. Lumateperone received Fast Track designation from the FDA in November 2017 for the treatment of schizophrenia.
Our first NDA submission represents a significant milestone for the Company and the development of lumateperone, which we believe has the potential to be an important advance in the treatment of schizophrenia. We look forward to the prospect of working with the FDA to bring lumateperone to patients living with this debilitating disease as quickly as possible, said Dr. Sharon Mates, Chairman and CEO of Intra-Cellular Therapies.

Takeda, Lundbeck Apply in Japan for Depression Treatment


Takeda Pharmaceutical Company Limited (TSE: 4502)(“Takeda”) and its partner, H. Lundbeck A/S (“Lundbeck”) today announced the submission of a New Drug Application (“NDA”) to the Ministry of Health, Labour and Welfare in Japan for vortioxetine for the treatment of Major Depressive Disorder (MDD) in adults. MDD is a complex but common disorder with more than 3.5 million cases in Japan, affecting 3percent of the population[i].
The NDA filing included data from the pivotal phase III randomized, placebo-controlled study (NCT02389816) in MDD. Approximately 490 Japanese adults with recurrent MDD were randomized to receive vortioxetine (10 and 20 mg) or placebo. The primary endpoint was the change from baseline (i.e. the start of double-blind treatment) in the Montgomery-Asberg Depression Rating Scale (MADRS) total score after 8 weeks of treatment. The study demonstrated positive results of vortioxetine as compared to placebo for the treatment of MDD in adults. Full results will be presented at a scientific meeting in the future. The regulatory submission also featured data from three other key studies conducted globally (NCT01255787) and in Japan (NCT01355081, NCT01395147).
“MDD is a multifaceted condition that has emotional, physical and cognitive symptoms. As such, it represents a significant medical need.” said Naoyoshi Hirota, head of Takeda Development Center Japan. “We are pleased by today’s regulatory filing as it demonstrates our joint commitment with Lundbeck, and our belief that vortioxetine has the potential to become a new treatment option for patients in Japan suffering from this serious and complex condition.”

Rensselaer Polytechnic, United Health Put Up $1M to Train Health Data Experts


  • Training will take place through the “Rensselaer Health INCITE Pipeline”
  • Funding supports new entry points into health informatics and experiential learning opportunities
Rensselaer Polytechnic Institute and the United Health Foundation are expanding access to health informatics educational opportunities and applied health data science research experiences through the Rensselaer Institute for Data Exploration and Application (IDEA).
The Rensselaer-United Health Foundation partnership aims to address the growing need for a larger workforce of health data analysts and technologists. The three-year, $1.1 million grant from the United Health Foundation will help launch the “Rensselaer Health Informatics Challenges in Technology Education (INCITE) Pipeline” to prepare students for careers in health data science through several interrelated initiatives, including:
  • enhancing curricula to make health informatics more accessible to students from an array of majors such as biology and mathematics;
  • creating a new “synthetic data generator” to expose students to real-world health data challenges and test solutions; and
  • promoting experiential learning through online challenges available to students at Rensselaer and around the world.
“Rensselaer Polytechnic Institute is a leader in bringing together the physical, digital and biological worlds to drive research innovations and distinct educational opportunities,” said Rensselaer President Dr. Shirley Ann Jackson. “Our partnership with the United Health Foundation will enable us to expand opportunities for researchers and students to tackle the tough challenges of our health care system through the integration of human intelligence with machine intelligence.”
The grant specifically supports the work of the Rensselaer Institute for Data Exploration and Application (IDEA), which enables data science research and education across the Rensselaer campus. The partnership will yield a larger pipeline of students pursuing data science careers in health care, and novel teaching methods that improve undergraduate health informatics education at Rensselaer and beyond.
“The United Health Foundation is honored to partner with Rensselaer to help create a 21st century health care workforce ready to meet the health needs of the nation and the world,” said Dr. Paul Bleicher, a Rensselaer alumnus and CEO of OptumLabs, a UnitedHealth Group company. “Investing in tomorrow’s health care data scientists is vital to helping solve some of the health system’s toughest challenges and creating the actionable insights we need for better care quality and health outcomes.”